Loading
A phase 2 trial of Camrelizumab, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by CrystalGenomics, Inc., now recruiting.
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05841472 by CrystalGenomics, Inc., with 60 participants planned, started 2023-08-23 and due to reach its primary completion in 2026-08. Interventions recorded: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin. Conditions listed: Non Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.
Shares Camrelizumab, Pemetrexed, Platinum agents, Carboplatin.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/